Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Latest Articles
Submit an article Journal homepage
3
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database

Michael B. Andrewsa Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USAORCID Iconhttps://orcid.org/0000-0002-2969-4769View further author information
ORCID Icon &
Douglas G. Adlerb Center for Advanced Therapeutic Endoscopy (CATE), Porter Adventist Hospital/PEAK Gastroenterology, Denver, CO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3214-6285View further author information
ORCID Icon
Received 19 Mar 2024, Accepted 11 Jul 2024, Published online: 15 Jul 2024

References

  • Sullivan A, Temperley L, Ruban RA. Pathophysiology, aetiology and treatment of gastroparesis. Dig Dis Sci. 2020 Jun;65(6):1615–1631. doi: 10.1007/s10620-020-06287-2 PMID: 32350720.
  • Ye Y, Yin Y, Huh SY, et al. Epidemiology, etiology, and treatment of gastroparesis: real-world evidence from a large US national claims database. Gastroenterology. 2022 Jan;162(1):109–121.e5. doi: 10.1053/j.gastro.2021.09.064 Epub 2021 Oct 6. PMID: 34624355.
  • Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010;5(5):653–662. doi: 10.1586/eem.10.41 PMID: 21278804; PMCID: PMC3027056.
  • Lin J, Thompson TJ, Cheng YJ, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metr. 2018 Jun 15;16(1):9. doi: 10.1186/s12963-018-0166-4 PMID: 29903012; PMCID: PMC6003101.
  • Questions and answers on FDA’s adverse event reporting system (FAERS) [internet]. FDA; 2018 [cited 2024 Feb 6]. Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers
  • von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008 Apr;61(4):344–9. doi: 10.1016/j.jclinepi.2007.11.008 PMID: 18313558.
  • Sanger GJ, Andrews PLR. Review article: an analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis. Aliment Pharmacol Ther. 2023 May;57(9):962–978. doi: 10.1111/apt.17466 Epub 2023 Mar 14. PMID: 36919196.
  • Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745–767. doi: 10.1111/j.1365-2036.2012.05011.x Epub 2012 Feb 22. PMID: 22356640; PMCID: PMC3491670.
  • Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18(4):701–715. doi: 10.1093/schbul/18.4.701 PMID: 1359633.
  • Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2010 Jun;19(6):765–775. doi: 10.1517/13543784.2010.482927 PMID: 20408739.
  • Karayol R, Medrihan L, Warner-Schmidt JL, et al. Serotonin receptor 4 in the hippocampus modulates mood and anxiety. Mol Psychiatry. 2021 Jun;26(6):2334–2349. doi: 10.1038/s41380-020-00994-y Epub 2021 Jan 13. PMID: 33441982; PMCID: PMC8275670.
  • Murphy SE, de Cates AN, Gillespie AL, et al. Translating the promise of 5HT4 receptor agonists for the treatment of depression. Psychol Med. 2021;51(7):1111–1120. doi: 10.1017/S0033291720000604
  • Mendez-David I, David DJ, Darcet F, et al. Rapid anxiolytic effects of a 5-HT₄ receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology. 2014 May;39(6):1366–1378. doi: 10.1038/npp.2013.332 Epub 2013 Nov 28. PMID: 24287720; PMCID: PMC3988540.
  • Woodhouse S, Hebbard G, Knowles SR. Psychological controversies in gastroparesis: a systematic review. World J Gastroenterol. 2017 Feb 21;23(7):1298–1309. doi: 10.3748/wjg.v23.i7.1298 PMID: 28275310; PMCID: PMC5323455.
  • Bach T, Syversveen T, Kvingedal AM, et al. 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol. 2001 Feb;363(2):146–160. doi: 10.1007/s002100000299 PMID: 11218067.
  • Tameez Ud Din A, Khan AH, Bajwa H, et al. Clinical efficacy and safety profile of prucalopride in chronic idiopathic constipation. Cureus. 2019 Apr 4;11(4):e4382. doi: 10.7759/cureus.4382 PMID: 31218146; PMCID: PMC6553670.
  • Leonard JB, Munir KM, Kim HK. Metoclopramide induced pheochromocytoma crisis. Am J Emerg Med. 2018 Jun;36(6):e1124.1–e1124.2. doi: 10.1016/j.ajem.2018.03.009 Epub 2018 Mar 5. PMID: 29534916.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.